Kliniken Essen-Mitte

Diagnosis and Treatment of Endometriosis. Guideline of the DGGG, SGGG and OEGGG (S2k Level, AWMF Registry Number 015/045, August 2020) (2021) Burghaus S, Schäfer SD, Beckmann M, Brandes I, Brünahl C, Chvatal R, Drahoå ovský J, et al. Journal article Ribecca - a phase 3b, multi-center, open label study for women with estrogen receptor positive, locally advanced or metastatic breast cancer treated with ribociclib (lee011) in combination with letrozole: Final results (2021) Reinisch M, Nusch A, Decker T, Hartkopf A, Heinrich BJ, Kurbacher CM, Fuchs R, et al. Conference contribution Adjuvant radiotherapy and local recurrence in vulvar cancer – a subset analysis of the AGO-CaRE-1 study (2021) Woelber L, Prieske K, Eulenburg Cz, Corradini S, Petersen C, Bommert M, Blankenstein T, et al. Journal article Erratum: AGO Recommendations for the Surgical Therapy of the Axilla after Neoadjuvant Chemotherapy: 2021 Update (Geburtshilfe Frauenheilkd (2021) 81:10 (1112-1120) DOI: 10.1055/a-1499-8431) (2021) Friedrich M, Kühn T, Janni W, Müller V, Banys-Paluchowski M, Kolberg-Liedtke C, Jackisch C, et al. Journal article, Erratum PACIFIC-R real-world study: Treatment duration and interim analysis of progression-free survival in unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy (2021) Girard N, Smit HJM, Sibille A, Mcdonald F, Mornex F, Garassino MCC, Filippi AR, et al. Conference contribution Efficacy and safety of ribociclib (RIB) in combination with letrozole (LET) in patients with estrogen receptorepositive advanced breast cancer (ABC): Secondary and exploratory results of phase 3b RIBECCA study (2021) Decker T, Fasching P, Nusch A, Hartkopf A, Heinrich BJ, Kurbacher CM, Fuchs R, et al. Conference contribution Phase III post-neoadjuvant study evaluating sacituzumab govitecan (SG), an antibody drug conjugate in primary HER2-negative breast cancer patients with high relapse risk after standard neoadjuvant treatment: SASCIA (2021) Marme F, Hanusch C, Furlanetto J, Denkert C, Link T, Untch M, Blohmer JU, et al. Conference contribution A multicenter, randomized, double-blind, phase II study to evaluate the tolerability of an induction dose escalation of everolimus in patients with metastatic breast cancer (mBC) (DESIREE) (2021) Loibl S, Schmidt M, Luebbe K, Decker T, Thill M, Bauer L, Mueller V, et al. Conference contribution AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2021 (2021) Ditsch N, Kolberg-Liedtke C, Friedrich M, Jackisch C, Albert US, Banys-Paluchowski M, Bauerfeind I, et al. Journal article, Review article AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2021 (2021) Thill M, Friedrich M, Kolberg-Liedtke C, Albert US, Banys-Paluchowski M, Bauerfeind I, Blohmer JU, et al. Journal article, Review article